Author:
Brandes F.,Striefler J. K.,Dörr A.,Schmiester M.,Märdian S.,Koulaxouzidis G.,Kaul D.,Behzadi A.,Thuss-Patience P.,Ahn J.,Pelzer U.,Bullinger L.,Flörcken A.
Abstract
Abstract
Background
Soft tissue sarcomas (STS) account for less than 1% of all malignancies. Approximately 50% of the patients develop metastases with limited survival in the course of their disease. For those patients, palliative treatment aiming at symptom relief and improvement of quality of life is most important. However, data on symptom burden and palliative intervention are limited in STS patients.
Aim
Our study evaluates the effectiveness of a palliative care intervention on symptom relief and quality of life in STS patients.
Design/setting
We retrospectively analysed 53 inpatient visits of 34 patients with advanced STS, admitted to our palliative care unit between 2012 and 2018.
Symptom burden was measured with a standardised base assessment questionnaire at admission and discharge.
Results
Median disease duration before admission was 24 months, 85% of patients had metastases. The predominant indication for admission was pain, weakness and fatigue. Palliative care intervention led to a significant reduction of pain: median NRS for acute pain was reduced from 3 to 1 (p < 0.001), pain within the last 24 h from 5 to 2 (p < 0.001) and of the median MIDOS symptom score: 18 to 13 (p < 0.001). Also, the median stress level, according to the distress thermometer, was reduced significantly: 7.5 to 5 (p = 0.027).
Conclusions
Our data underline that specialised palliative care intervention leads to significant symptom relief in patients with advanced STS. Further efforts should aim for an early integration of palliative care in these patients focusing primarily on the identification of subjects at high risk for severe symptomatic disease.
Publisher
Springer Science and Business Media LLC
Reference29 articles.
1. Jo VY, Fletcher CDM. WHO classification of soft tissue tumours: an update based on the 2013 (4th) edition. Pathology (Phila). 2014 Feb;46(2):95–104.
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34.
3. Cancer of soft tissue including heart - Cancer Stat Facts. SEER. [cited 2019 Dec 1]. Available from: https://seer.cancer.gov/statfacts/html/soft.html.
4. Judson I, Verweij J, Gelderblom H, Hartmann JT, Schöffski P, Blay J-Y, et al. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. Lancet Oncol. 2014;15(4):415–23.
5. Reichardt P, Leahy M, Garcia Del Muro X, Ferrari S, Martin J, Gelderblom H, et al. Quality of Life and Utility in Patients with Metastatic Soft Tissue and Bone Sarcoma: The Sarcoma Treatment and Burden of Illness in North America and Europe (SABINE) Study. Sarcoma. 2012;2012:740279.
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献